菌状息肉症治療の世界市場レポート 2025年

菌状息肉症治療市場規模は、今後数年間で力強い成長が見込まれます。2029年には年間平均成長率（CAGR）6.8％で13億5,000万米ドルに成長します。予測期間の成長は、ヘルスケアインフラの進歩、患者人口の増加、不衛生なライフスタイルによる菌状息肉症の有病率の増加に起因しています。予測期間における主な動向としては、化学療法に伴う治療技術の進歩、ファーストライン治療としてのモノクローナル抗体の需要増加、先進的新製品の発売、研究開発投資の増加などが挙げられます。

リンパ腫の罹患率の増加は、今後の菌状息肉症治療市場の拡大を牽引すると予想されます。リンパ腫は、リンパ節、脾臓、胸腺、骨髄からなるリンパ系を侵すがんであり、環境暴露、ウイルス感染、高齢化、ライフスタイルの選択など様々な要因により増加傾向にあります。菌状息肉症の治療には、局所副腎皮質ステロイド、光線療法、全身療法などがあり、皮膚T細胞リンパ腫の管理において、皮膚病変のコントロール、症状の緩和、リンパ腫患者の病勢進行の管理などに利用されています。例えば、2024年1月、米国がん学会によると、非ホジキンリンパ腫（NHL）は米国で最も罹患率の高いがんの一つであり、全がん症例の約4％を占める。2024年には、約8万620人（男性4万4,590人、女性3万6,030人）が非ホジキンリンパ腫と診断され、約2万140人（男性1万1,780人、女性8,360人）がこのがんで死亡すると推定されています。したがって、リンパ腫の罹患率の増加が菌状息肉症治療市場の成長を促進しています。

菌状息肉症治療市場の主なプレーヤーは、治療効果と特異性を高めるためにCAR T細胞療法などの先進的な治療法の開発に注力しています。免疫療法の一種であるCAR T細胞療法は、菌状息肉症に関連するがん細胞を含むがん細胞をよりよく認識し、標的とするように患者のT細胞を遺伝子改変することを含みます。例えば、2022年9月、スイスを拠点とするバイオテクノロジー企業CRISPR Therapeutics AGは、米国食品医薬品局（FDA）が、菌状息肉症およびセザリー症候群（MFまたはSS）の治療薬として、CD70を標的とする同社の同種CAR T細胞療法であるCTX130に再生医療先進療法（RMAT）の指定を与えたと発表しました。この指定は、CTX130プログラムにとって重要なマイルストーンであり、有望な臨床データに基づいてT細胞リンパ腫の治療におけるこの細胞治療の可能性が認められたことを意味します。RMATの指定は、21世紀治療法に基づいて設立されたプログラムの一環で、重篤な疾患や生命を脅かす疾患の治療を目的とする遺伝子治療薬の医薬品開発および審査プロセスを迅速化するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、新型コロナウイルス感染症、そして景気回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界菌状息肉症治療PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の菌状息肉症治療市場：成長率分析
• 世界の菌状息肉症治療市場の実績：規模と成長, 2019-2024
• 世界の菌状息肉症治療市場の予測：規模と成長, 2024-2029, 2034F
• 世界菌状息肉症治療総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の菌状息肉症治療市場薬剤の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所ステロイド
• メクロレタミン
• 世界の菌状息肉症治療市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 光線力学療法
• 放射線治療
• 標的療法
• 化学療法
• 世界の菌状息肉症治療市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 個人クリニック
• 専門クリニック
• 世界の菌状息肉症治療市場、局所ステロイドの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• コルチコステロイドクリームまたは軟膏（ヒドロコルチゾン、クロベタゾール）
• 局所ステロイドローション
• 世界の菌状息肉症治療市場メクロレタミンの種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 局所用メクロレタミン（ナイトロジェンマスタードクリーム）
• 注射用メクロレタミン

第7章 地域別・国別分析

• 世界の菌状息肉症治療市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の菌状息肉症治療市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 菌状息肉症治療市場：競合情勢
• 菌状息肉症治療市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• GlaxoSmithKline plc
• Tocris Bioscience
• Viatris Inc.
• Astellas Pharma Inc.
• Daiichi Sankyo Company
• Takeda Pharmaceutical Company Limited
• Bausch Health
• Eisai Co. Ltd.
• Horizon Therapeutics plc
• Varian Medical Systems
• Kyowa Kirin Co. Ltd.
• Seattle Genetics Inc.
• Azurity Pharmaceuticals Inc.
• Innate Pharma S.A.
• Helsinn Therapeutics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 菌状息肉症治療市場2029：新たな機会を提供する国
• 菌状息肉症治療市場2029：新たな機会を提供するセグメント
• 菌状息肉症治療市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Mycosis fungoides treatment encompasses a range of therapies, medications, and procedures aimed at managing and alleviating symptoms associated with cutaneous T-cell lymphoma, a rare type of non-Hodgkin lymphoma primarily affecting the skin. Treatment approaches typically involve a combination of therapies, including topical medications and systemic treatments such as immunotherapy, tailored to the specific stage and severity of the disease.

The primary types of mycosis fungoides treatment include topical steroids and mechlorethamine. Topical steroids are applied directly to the skin to reduce inflammation and irritation. Other treatment modalities encompass photodynamic therapy, radiation therapy, targeted therapy, and chemotherapy, utilized across various healthcare settings such as hospitals, private clinics, and specialty clinics.

The mycosis fungoides treatment market research report is one of a series of new reports from The Business Research Company that provides mycosis fungoides treatment market statistics, including mycosis fungoides treatment industry global market size, regional shares, competitors with a mycosis fungoides treatment market share, detailed mycosis fungoides treatment market segments, market trends and opportunities, and any further data you may need to thrive in the mycosis fungoides treatment industry. This mycosis fungoides treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The mycosis fungoides treatment market size has grown strongly in recent years. It will grow from $0.97 billion in 2024 to $1.04 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to increased incidences of immune system dysfunction, inflating utilization of efficacious therapeutics, widespread adoption of phototherapy, rise in usage of radiation therapy, and the increased popularity of supportive care measures.

The mycosis fungoides treatment market size is expected to see strong growth in the next few years. It will grow to $1.35 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to advancements in healthcare infrastructure, increasing patient population, and increase in prevalence of mycosis fungoides due to unhygienic lifestyles. Major trends in the forecast period include technological advancements in treatment associated with chemotherapy, a rise in demand for monoclonal antibodies as first-line therapy, the launch of new advanced products, and increasing investment in research and development.

The increasing incidence of lymphoma cancer is expected to drive the expansion of the mycosis fungoides treatment market in the future. Lymphoma, a cancer affecting the lymphatic system comprising lymph nodes, spleen, thymus gland, and bone marrow, is on the rise due to various factors such as environmental exposures, viral infections, an aging population, and lifestyle choices. Mycosis fungoides treatments, including topical corticosteroids, phototherapy, and systemic therapies, are utilized in managing cutaneous T-cell lymphomas to control skin lesions, alleviate symptoms, and manage disease progression in lymphoma patients. For example, in January 2024, according to the American Cancer Society, non-Hodgkin lymphoma (NHL) ranked among the most prevalent cancers in the United States, constituting about 4% of all cancer cases. It was estimated that around 80,620 individuals (44,590 males and 36,030 females) would be diagnosed with NHL, with approximately 20,140 people (11,780 males and 8,360 females) succumbing to this cancer in 2024. Hence, the increasing incidence of lymphoma cancer is fueling the growth of the mycosis fungoides treatment market.

Key players in the mycosis fungoides treatment market are focusing on developing advanced therapies such as CAR T cell therapy to enhance treatment efficacy and specificity. CAR T cell therapy, a form of immunotherapy, involves genetically modifying a patient's T cells to better recognize and target cancer cells, including those associated with mycosis fungoides. For instance, in September 2022, CRISPR Therapeutics AG, a Switzerland-based biotech company, announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to CTX130, the company's allogeneic CAR T cell therapy targeting CD70, for treating Mycosis Fungoides and Sezary Syndrome (MF or SS). This designation signifies a significant milestone for the CTX130 program, acknowledging the potential of this cell therapy in treating T-cell lymphomas based on promising clinical data. The RMAT designation is part of a program established under the 21st Century Cures Act to expedite drug development and review processes for genetic therapies intended to treat severe or life-threatening diseases.

In October 2023, Shorla Oncology, an Ireland-based pharmaceutical company, acquired Jylamvo from Therakind for an undisclosed amount. This acquisition allows Shorla to introduce Jylamvo to the US market, where it has been approved for treating conditions such as acute lymphoblastic leukemia and mycosis fungoides. Therakind Limited, a UK-based pharmaceutical company, specializes in developing niche medicines.

Major companies operating in the mycosis fungoides treatment market are Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb, Abbott Laboratories, Novartis AG, GlaxoSmithKline plc, Tocris Bioscience, Viatris Inc., Astellas Pharma Inc., Daiichi Sankyo Company, Takeda Pharmaceutical Company Limited, Bausch Health, Eisai Co. Ltd., Horizon Therapeutics plc, Varian Medical Systems, Kyowa Kirin Co. Ltd., Seattle Genetics Inc., Azurity Pharmaceuticals Inc., Innate Pharma S.A., Helsinn Therapeutics, Jubilant Cadista Pharmaceuticals Inc., Elorac Inc., Soligenix Inc., Ceptaris Therapeutics Inc.

North America was the largest region in the mycosis fungoides treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mycosis fungoides treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the mycosis fungoides treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mycosis fungoides treatment market consists of revenues earned by entities by providing services, such as phototherapy, dermatological care, and specialized therapies. The market value includes the value of related services provided by the treatment creators or included within the treatment offering. The mycosis fungoides treatment market also includes sales of oral retinoids, interferons, monoclonal antibodies, and nitrogen mustard. Values in this market are 'factory gate' values, that is, the value of treatments sold by the manufacturers or creators of the treatments, whether to other entities (including downstream healthcare providers and pharmacies) or directly to end customers. The value of treatments in this market includes related services sold by the creators of the treatments.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Mycosis Fungoides Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on mycosis fungoides treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for mycosis fungoides treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The mycosis fungoides treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Type: Topical Steroids; Mechlorethamine
• 2) By Treatment Type: Photodynamic Therapy; Radiation Therapy; Targeted Therapy; Chemotherapy
• 3) By End-user: Hospitals; Private Clinics; Specialty Clinics
• Subsegments:
• 1) By Topical Steroids: Corticosteroid Creams Or Ointments ( Hydrocortisone, Clobetasol); Topical Steroid Lotions
• 2) By Mechlorethamine: Topical Mechlorethamine ( Nitrogen Mustard Cream); Injectable Mechlorethamine
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Bristol Myers Squibb; Abbott Laboratories; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Mycosis Fungoides Treatment Market Characteristics

3. Mycosis Fungoides Treatment Market Trends And Strategies

4. Mycosis Fungoides Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Mycosis Fungoides Treatment Growth Analysis And Strategic Analysis Framework

• 5.1. Global Mycosis Fungoides Treatment PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Mycosis Fungoides Treatment Market Growth Rate Analysis
• 5.4. Global Mycosis Fungoides Treatment Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Mycosis Fungoides Treatment Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Mycosis Fungoides Treatment Total Addressable Market (TAM)

6. Mycosis Fungoides Treatment Market Segmentation

• 6.1. Global Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Steroids
• Mechlorethamine
• 6.2. Global Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Photodynamic Therapy
• Radiation Therapy
• Targeted Therapy
• Chemotherapy
• 6.3. Global Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Private Clinics
• Specialty Clinics
• 6.4. Global Mycosis Fungoides Treatment Market, Sub-Segmentation Of Topical Steroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Corticosteroid Creams Or Ointments (Hydrocortisone, Clobetasol)
• Topical Steroid Lotions
• 6.5. Global Mycosis Fungoides Treatment Market, Sub-Segmentation Of Mechlorethamine, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Topical Mechlorethamine (Nitrogen Mustard Cream)
• Injectable Mechlorethamine

7. Mycosis Fungoides Treatment Market Regional And Country Analysis

• 7.1. Global Mycosis Fungoides Treatment Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Mycosis Fungoides Treatment Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Mycosis Fungoides Treatment Market

• 8.1. Asia-Pacific Mycosis Fungoides Treatment Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Mycosis Fungoides Treatment Market

• 9.1. China Mycosis Fungoides Treatment Market Overview
• 9.2. China Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Mycosis Fungoides Treatment Market

• 10.1. India Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Mycosis Fungoides Treatment Market

• 11.1. Japan Mycosis Fungoides Treatment Market Overview
• 11.2. Japan Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Mycosis Fungoides Treatment Market

• 12.1. Australia Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Mycosis Fungoides Treatment Market

• 13.1. Indonesia Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Mycosis Fungoides Treatment Market

• 14.1. South Korea Mycosis Fungoides Treatment Market Overview
• 14.2. South Korea Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Mycosis Fungoides Treatment Market

• 15.1. Western Europe Mycosis Fungoides Treatment Market Overview
• 15.2. Western Europe Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Mycosis Fungoides Treatment Market

• 16.1. UK Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Mycosis Fungoides Treatment Market

• 17.1. Germany Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Mycosis Fungoides Treatment Market

• 18.1. France Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Mycosis Fungoides Treatment Market

• 19.1. Italy Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Mycosis Fungoides Treatment Market

• 20.1. Spain Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Mycosis Fungoides Treatment Market

• 21.1. Eastern Europe Mycosis Fungoides Treatment Market Overview
• 21.2. Eastern Europe Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Mycosis Fungoides Treatment Market

• 22.1. Russia Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Mycosis Fungoides Treatment Market

• 23.1. North America Mycosis Fungoides Treatment Market Overview
• 23.2. North America Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Mycosis Fungoides Treatment Market

• 24.1. USA Mycosis Fungoides Treatment Market Overview
• 24.2. USA Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Mycosis Fungoides Treatment Market

• 25.1. Canada Mycosis Fungoides Treatment Market Overview
• 25.2. Canada Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Mycosis Fungoides Treatment Market

• 26.1. South America Mycosis Fungoides Treatment Market Overview
• 26.2. South America Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Mycosis Fungoides Treatment Market

• 27.1. Brazil Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Mycosis Fungoides Treatment Market

• 28.1. Middle East Mycosis Fungoides Treatment Market Overview
• 28.2. Middle East Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Mycosis Fungoides Treatment Market

• 29.1. Africa Mycosis Fungoides Treatment Market Overview
• 29.2. Africa Mycosis Fungoides Treatment Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Mycosis Fungoides Treatment Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Mycosis Fungoides Treatment Market, Segmentation By End-user, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Mycosis Fungoides Treatment Market Competitive Landscape And Company Profiles

• 30.1. Mycosis Fungoides Treatment Market Competitive Landscape
• 30.2. Mycosis Fungoides Treatment Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Abbott Laboratories Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Mycosis Fungoides Treatment Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Tocris Bioscience
• 31.3. Viatris Inc.
• 31.4. Astellas Pharma Inc.
• 31.5. Daiichi Sankyo Company
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Bausch Health
• 31.8. Eisai Co. Ltd.
• 31.9. Horizon Therapeutics plc
• 31.10. Varian Medical Systems
• 31.11. Kyowa Kirin Co. Ltd.
• 31.12. Seattle Genetics Inc.
• 31.13. Azurity Pharmaceuticals Inc.
• 31.14. Innate Pharma S.A.
• 31.15. Helsinn Therapeutics

32. Global Mycosis Fungoides Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Mycosis Fungoides Treatment Market

34. Recent Developments In The Mycosis Fungoides Treatment Market

35. Mycosis Fungoides Treatment Market High Potential Countries, Segments and Strategies

• 35.1 Mycosis Fungoides Treatment Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Mycosis Fungoides Treatment Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Mycosis Fungoides Treatment Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer